CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies.
about
Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic CriteriaMild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's diseaseComparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up studyAnesthesia in presymptomatic Alzheimer's disease: a study using the triple-transgenic mouse model.Prediction of conversion from mild cognitive impairment to Alzheimer disease based on bayesian data mining with ensemble learning.Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.Exercise and Alzheimer's disease biomarkers in cognitively normal older adults.Diagnostic tools for alzheimer's disease dementia and other dementias: an overview of diagnostic test accuracy (DTA) systematic reviewsAssessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions.Improving CSF Biomarkers' Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimer's Disease by Considering Different Confounding Factors: A Meta-Analysis.Sensitivity and specificity of diagnostic accuracy in Alzheimer's disease: a synthesis of existing evidence.Biomarkers in Alzheimer's disease.CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.Cerebrospinal fluid β-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease--systematic review and meta-analysis.Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature.Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.A correlativity study of plasma APL1β28 and clusterin levels with MMSE/MoCA/CASI in aMCI patients.Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.Perfusion Imaging with SPECT in the Era of Pathophysiology-Based Biomarkers for Alzheimer's Disease.Tau and p-tau as CSF biomarkers in dementia: a meta-analysis.Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias.Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.Amyloid-β as a biomarker for Alzheimer's disease: quantification methods in body fluids.Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer's disease.Alzheimer CSF biomarkers in routine clinical setting.In vivo parahippocampal white matter pathology as a biomarker of disease progression to Alzheimer's disease.Biofluid biomarkers of traumatic brain injury.Reproducibility of Alzheimer's Disease Cerebrospinal Fluid-Biomarker Measurements under Clinical Routine Conditions.[Cognitive deficits in unipolar major depression].
P2860
Q26864063-9016717A-EBB4-4CAD-97FA-232162F0E226Q27027319-F98F38DD-950C-415E-9BB7-C79099577E8BQ28728080-538BCAFA-4389-44AC-A4B8-7CAA6488F429Q30503957-956D21AA-9953-425E-93F6-9DF6D5670FE5Q30666491-DC16C639-29AD-4EE2-B6E6-E38103FFA983Q31155412-CCD952AF-B378-46DD-B343-A7D8B750E967Q34116194-451297D9-B588-49C9-A1C2-CBE40991D9A7Q34306619-A94A6265-BA30-446E-9982-1F445C80CBA3Q34318022-7AC81D64-83A2-4F6B-9E2A-C9A4710B0E12Q34349522-32932E51-678E-403A-A282-10DD539C6FBEQ34728483-5AE68C10-0537-400F-A5F5-9E046457CC4CQ35113795-2061B125-648B-406A-BE6C-89B436679EE8Q35114771-BDD0A2A1-5515-49A1-A475-9A39ED5E49B9Q35117772-5125879D-FFF1-4227-9506-700548B825D4Q35166684-0520993A-F5BB-4F01-B4AB-697A0826AB53Q36157458-5E3681D7-FC7B-44CA-AC40-E40827DD03DBQ36209423-A9D0A581-B479-4C96-82C4-637768B4CB12Q36412536-3D472D04-5C2B-4454-9C89-D43BD282F296Q37524486-9D258816-435E-4F21-A3E1-D95F4957A245Q37810697-5A59ACAA-6556-430C-9024-9A7DF5CFD6B8Q37825442-ACBE54BB-0C2E-44FD-AB8B-4DBD5FBCE63EQ37845820-016AA73F-E719-499D-B0D2-9EA80AFA363CQ37845821-343DC08B-E658-4DA0-A062-8A8C71419A00Q38044199-68B62EDD-7966-43EA-8292-BAC15F9F0D13Q38289739-14CB6983-665E-4051-99FA-E06EED94912DQ38543843-D4AA40E9-266F-4121-BFB2-2B20DC35DDA7Q41160304-73111514-1A12-42E5-B9E1-F3AB1B717877Q45205291-4F2407B9-29BC-46AC-BB29-482ABD9E0202Q45733857-73E27580-B4CE-4A99-B266-3ED4C2ADF964Q47605675-3DA50228-D589-4BD6-B211-3EEAC8AFC177Q50034469-2888F59C-933E-4BBE-9BE9-9AB422615A17Q50757194-0337F1D5-29F4-42CE-BB60-CA63310E1513
P2860
CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CSF phosphorylated tau in the ...... a meta-analysis of 51 studies.
@en
CSF phosphorylated tau in the ...... a meta-analysis of 51 studies.
@nl
type
label
CSF phosphorylated tau in the ...... a meta-analysis of 51 studies.
@en
CSF phosphorylated tau in the ...... a meta-analysis of 51 studies.
@nl
prefLabel
CSF phosphorylated tau in the ...... a meta-analysis of 51 studies.
@en
CSF phosphorylated tau in the ...... a meta-analysis of 51 studies.
@nl
P921
P356
P1476
CSF phosphorylated tau in the ...... a meta-analysis of 51 studies
@en
P2093
A J Mitchell
P304
P356
10.1136/JNNP.2008.167791
P407
P577
2009-05-21T00:00:00Z